- Home
- PFL vs MREO Comparison
PFL vs MREO Comparison
Compare PFL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- MREO
- Stock Information
- Founded
- PFL 2003
- MREO 2015
- Country
- PFL United States
- MREO United Kingdom
- Employees
- PFL N/A
- MREO N/A
- Industry
- PFL Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- MREO Health Care
- Exchange
- PFL Nasdaq
- MREO Nasdaq
- Market Cap
- PFL 375.4M
- MREO 438.8M
- IPO Year
- PFL N/A
- MREO N/A
- Fundamental
- Price
- PFL $8.37
- MREO $2.75
- Analyst Decision
- PFL
- MREO Strong Buy
- Analyst Count
- PFL 0
- MREO 5
- Target Price
- PFL N/A
- MREO $7.60
- AVG Volume (30 Days)
- PFL 113.7K
- MREO 1.3M
- Earning Date
- PFL 01-01-0001
- MREO 08-12-2025
- Dividend Yield
- PFL 11.53%
- MREO N/A
- EPS Growth
- PFL N/A
- MREO N/A
- EPS
- PFL N/A
- MREO N/A
- Revenue
- PFL N/A
- MREO N/A
- Revenue This Year
- PFL N/A
- MREO N/A
- Revenue Next Year
- PFL N/A
- MREO $52.34
- P/E Ratio
- PFL N/A
- MREO N/A
- Revenue Growth
- PFL N/A
- MREO N/A
- 52 Week Low
- PFL $6.98
- MREO $1.58
- 52 Week High
- PFL $8.62
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- PFL 60.19
- MREO 54.81
- Support Level
- PFL $8.30
- MREO $2.63
- Resistance Level
- PFL $8.35
- MREO $2.85
- Average True Range (ATR)
- PFL 0.04
- MREO 0.14
- MACD
- PFL 0.00
- MREO -0.02
- Stochastic Oscillator
- PFL 99.92
- MREO 35.50
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).